Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.5052W HIGH $5.45
Volume
4.85 M
Value Traded
4.45 M
Short % Float
11.74%
-6.07%Week
-19.15%1 Month
-12.92%3 Month
+0.72%6 Month
+55.36%5 Year
-39.73%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
828.08 M
EPS (TTM)
0.77
P/E Ratio
5.41
Ent. Value
735.46 M
Total Shares
198.11 M
Float Shares
157.48 M
Insiders
20.51%
Institutions
65.87%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ABUS Catalyst Timeline
Dated clinical, regulatory and corporate events for Arbutus Biopharma Corporation
Catalyst Timeline
Dated clinical, regulatory & corporate events for Arbutus Biopharma Corporation
762Total events
5Upcoming
207Tier-1 (high impact)
2011 to 2027Coverage
Upcoming catalysts 2
Event history 50
●Equity OfferingCorporate
Payment and settlement of tender offer consideration to shareholders via Depositary
●Corporate ApprovalCorporate
Arbutus announces final results of US$230 million modified Dutch auction tender offer
●Equity OfferingCorporate
Preliminary results of tender offer announced: 46,000,000 shares at US$5.00
▼Equity OfferingCorporate
Arbutus completes US$230M modified Dutch auction tender offer, purchasing 46,000,000 shares at US$5.00
●Equity OfferingCorporate
Offer to purchase and issuer bid circular dated August 24, 2026 filed
▲Milestone PaymentCorporate
Expected receipt of $950M noncontingent settlement payment from Moderna
◆Timing GuidancePresentation
Evaluating return of capital to shareholders in Q3 2026 after Moderna payment
◆IP Litigation RulingIP / Competition
Unified Patent Court oral hearings for two international lawsuits against Moderna
▲Fast Track DesignationImdusiranDesignation
FDA grants Fast Track designation for imdusiran
chronic hepatitis Bsource ↗
▲Fast Track DesignationImdusiranDesignation
FDA granted Fast Track designation for imdusiran
chronic hepatitis Bsource ↗
▲Primary Endpoint MetImdusiranClinical Data
Two additional patients achieved functional cure in Phase 2a trials of imdusiran
chronic hepatitis Bsource ↗
◆IP Litigation RulingIP / Competition
Court rules on Moderna's summary judgment motion regarding 28 U.S.C. 1498, prosecution history estoppel, and patent validity
▲Milestone PaymentCorporate
Milestone payment received from Alnylam for LNP license for HCC product candidate
hepatocellular carcinomasource ↗
▼Restructuring LayoffsCorporate
Restructuring completed; remaining payments expected by Q1 2026
▲Full ResultsImdusiranClinical Data
Additional analysis of imdusiran Phase 2a data: 46% of patients met criteria to discontinue all treatment
chronic hepatitis Bsource ↗
◆Poster PresentationImdusiranPresentation
Elevated soluble immune biomarkers in subjects with HBsAg loss after imdusiran and immunotherapeutic agents
chronic hepatitis B virussource ↗
◆Poster PresentationAB-101Presentation
Safety, tolerability, PK/PD of multiple doses of AB-101 in chronic hepatitis B patients
chronic hepatitis B virussource ↗
▲Poster PresentationImdusiranPresentation
Poster presentation at AASLD 2025 showing beneficial clinical outcomes across HBV genotypes A to E from IM-PROVE I trial
chronic hepatitis Bsource ↗
▲Poster PresentationAB-101Presentation
Poster of Distinction at AASLD 2025 highlighting AB-101's maximal PD-L1 receptor occupancy at 30mg daily dose
chronic hepatitis Bsource ↗
●Runway Guidance UpdateCorporate
Cash, cash equivalents and marketable securities of $93.7M as of September 30, 2025
◆IP Litigation RulingIP / Competition
Jury trial in Moderna U.S. litigation scheduled for September 29, 2025
◆IP Litigation RulingIP / Competition
Trial date set for September 24, 2025 in Moderna lawsuit
◆IP Litigation RulingIP / Competition
Jury trial in US District Court for Delaware scheduled for September 2025
◆IP Litigation RulingIP / Competition
Moderna's Statement of Defense due in Unified Patent Court on July 8, 2025
◆IP Litigation RulingIP / Competition
Summary judgment phase begins in Moderna U.S. litigation
▲Partnership / LicenseImdusiranCorporate
Reacquired Greater China rights to imdusiran from Qilu Pharmaceutical
chronic hepatitis B virus (cHBV)source ↗
▲Full ResultsImdusiranClinical Data
Reported 8 patients achieved functional cure in Phase 2a trials
chronic hepatitis B virus (cHBV)source ↗
▲Partnership / LicenseImdusiranCorporate
Conclusion of Greater China partnership with Qilu Pharmaceutical for imdusiran
chronic hepatitis B virus (cHBV)source ↗
◆Poster PresentationImdusiranPresentation
Poster presentation: IM-PROVE I characterization of CHB subjects with functional cure or HBV DNA suppression after imdusiran plus IFN and NA discontinuation
chronic hepatitis Bsource ↗
◆Poster PresentationAB-101Presentation
Poster presentation: Preliminary safety, tolerability, PK/PD of single and multiple doses of AB-101 in healthy and CHB subjects
chronic hepatitis Bsource ↗
▲Late-BreakerImdusiranPresentation
Late-breaker poster presentation of end-of-study data from IM-PROVE II trial
chronic hepatitis Bsource ↗
▲Poster PresentationAB-101Presentation
Poster presentation of Part 3 data from Phase 1a/1b trial of AB-101
chronic hepatitis Bsource ↗
▲Poster PresentationImdusiranPresentation
Poster presentation of data from IM-PROVE I trial
chronic hepatitis Bsource ↗
Past FDA Catalysts and PDUFA Decisions
How ABUS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-11-13 | Imdusiran (AB-729) | Phase 2a data readout | Phase 2a |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D33 / 100
Pipeline Score
$95M
Pipeline Value
Richly Valued
Valuation Signal
3
Drugs Scored
0.1x
rNPV / MCap
Top 58%
Micro Cap(rank 382 of 658)
Percentile Rank
Arbutus Biopharma Corporation faces pipeline headwinds (33/100), with $238M risk-adjusted pipeline value, led by Imdusiran in Chronic Hepatitis B (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AB-729 Small moleculeCompletedNCT04980482 | Chronic Hepatitis b | Phase 2 | COMPLETED | 43 | May 21, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every ABUS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| imdusiran Fast Track | chronic hepatitis B | Phase 1/2 | 2025-10-07 | safe and well tolerated when administered at both 60 mg and 90 mg dose levels every 8 weeks for 4 · 6 doses (24 · 48 weeks); majority of subjects who achieved HBsAg response during pegylated interferon alfa-2a treatment with or following imdusiran dosing were genotype B or C; greater breadth and magnitude of immune biomarker increases were observed in IM-PROVE I subjects compared to IM-PROVE II; 83% mean maximal receptor occupancyRead More | Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Beardsley Robert ADirector | Option | 52,533 52,533 held | $3.20 | 09/18/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ABUS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Avidity Partners | 0.1 % | 525.00 K | 125.00 K |
ABUS Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ABUS ranks across every disease it competes in
Competitive Position is a premium feature
See how ABUS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialABUS News
ABUSArbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
Arbutus Biopharma Corporation has successfully completed a $230 million modified Dutch auction tender offer, purchasing 46 million shares at $5.00 each. The offer attracted significant interest, with 65.7 million shares tendered. Following the completion, approximately 153.3 million shares will remain outstanding. Shareholders who tendered above the purchase price were not accepted.
Read more →ABUSArbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
Arbutus Biopharma announced the preliminary results of its US$230 million modified Dutch auction tender offer, which expired on September 29, 2026. The company plans to purchase approximately 46 million shares at US$5.00 each, representing about 23% of its outstanding shares. The offer was oversubscribed, leading to a proration of shares for some tendering shareholders. Final results will be announced after verification by the Depositary.
Read more →ABUSArbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share
Arbutus Biopharma Corporation has launched a modified Dutch auction tender offer to repurchase up to $230 million of its common shares, priced between $5.00 and $5.75 per share. The offer, which begins on August 24, 2026, and ends on September 29, 2026, aims to provide liquidity to shareholders while enhancing overall shareholder value. The company has secured funding for this initiative through a recent settlement with Moderna.
Read more →ABUS▲ +9.2%on this newsshared move
Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer
Arbutus Biopharma Corporation announced its intent to initiate a modified 'Dutch Auction' tender offer to repurchase up to $230 million of its common shares. The offer will be priced between $5.00 and $5.75 per share and is expected to commence around August 24, 2026. This move follows a settlement with Moderna, which has been pivotal for the company.
Read more →ABUSArbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Arbutus Biopharma reported strong financial results for Q2 2026, maintaining $92.6 million in cash. The company received a $178 million settlement from Moderna and plans to return up to $230 million to shareholders. Additionally, it achieved alignment with the FDA on the Phase 2b trial design for imdusiran, which has received Fast Track designation for chronic hepatitis B treatment.
Read more →ABUSArbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders
Arbutus Biopharma has initiated three international lawsuits against Pfizer and BioNTech to enforce patents related to its lipid nanoparticle technology. The company has also received $178 million from Moderna as part of a settlement agreement and plans to return up to $230 million to shareholders. These actions reflect Arbutus' commitment to protecting its intellectual property and enhancing shareholder value.
Read more →ABUSArbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update
Arbutus Biopharma Corporation reported strong financial results for Q1 2026, with total revenue reaching $179.1 million, largely due to a settlement with Moderna. The FDA granted Fast Track designation for imdusiran, aimed at treating chronic hepatitis B, enhancing its development prospects. The company maintains a robust cash position of $95.2 million.
Read more →ABUSArbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
Arbutus Biopharma has received Fast Track designation from the FDA for its therapeutic imdusiran, aimed at treating chronic hepatitis B. This designation helps streamline the drug's development and review process, potentially leading to quicker access for patients. Imdusiran has previously demonstrated effective results, achieving functional cures in several patients during clinical trials. The company is optimistic about the continued collaboration with the FDA to facilitate the drug's progress through regulatory hurdles.
Read more →ABUSArbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
Arbutus Biopharma Corporation reported solid fourth quarter and year-end financial results for 2025, highlighting a cash position of $91.5 million. The company achieved a significant $2.25 billion settlement with Moderna over patent infringement related to lipid nanoparticle delivery technology. Additionally, two more patients from its imdusiran clinical trials reached functional cure status, reflecting progress in its hepatitis B program. However, the company reported a net loss of $33.5 million for the year, though this marks an improvement from the previous year's losses.
Read more →ABUSGenevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
Genevant Sciences and Arbutus Biopharma have reached a $2.25 billion settlement with Moderna to resolve patent infringement claims related to COVID-19 vaccines. Moderna will pay $950 million upfront and an additional $1.3 billion contingent on a favorable appeal outcome. This settlement marks a significant acknowledgment of Genevant's and Arbutus's contributions to mRNA vaccine technology.
Read more →ABUSCase No.
The article discusses the ongoing patent litigation between Arbutus Biopharma and Moderna. Arbutus asserts patent infringement claims against Moderna related to lipid nanoparticles used in its COVID-19 vaccine. Moderna has presented defenses, including expert opinions, but faces challenges due to previous inter partes review (IPR) decisions. The legal proceedings may have significant implications for both companies, particularly regarding their respective patent rights in the biotechnology field.
Read more →ABUSGenevant & Arbutus LNP Litigation Lindsay Androski Special Counsel, Genevant CEO, Arbutus Matt Gline CEO, Roivant
Genevant and Arbutus are actively involved in litigation against Moderna and Pfizer/BioNTech, alleging patent infringement regarding their lipid nanoparticle (LNP) technology used in COVID-19 vaccines. Initial court rulings have been favorable for Genevant, with significant revenue generated from the vaccines under dispute. However, the litigation process is expected to continue for several years, with key trials scheduled for 2026. The companies aim to secure restitution for the unauthorized use of their patents.
Read more →ABUS▼ -5.8%on this news
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Arbutus Biopharma reported its third quarter 2025 financial results, highlighting a strategic focus on its imdusiran program for chronic hepatitis B. The company noted that 46% of patients in Phase 2a trials were able to discontinue nucleos(t)ide analogue therapy. Despite a decrease in revenue and ongoing restructuring, the long-term efficacy of imdusiran remains promising.
Read more →ABUSArbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
Arbutus Biopharma Corporation announced that four abstracts, including clinical data on imdusiran and AB-101, have been accepted for presentation at AASLD – The Liver Meeting 2025. The AB-101 abstract has been designated as a Poster of Distinction. The findings highlight the safety and potential efficacy of imdusiran in chronic hepatitis B patients.
Read more →ABUSArbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Arbutus Biopharma reported its financial results for Q2 2025, showcasing a total revenue of $10.7 million, driven by the conclusion of its partnership with Qilu in Greater China. The company now holds global rights for its lead compound, imdusiran. Key personnel changes include the addition of Dr. Roger Sawhney to the Board and Dr. Harry Janssen to the Scientific Advisory Board. Despite the strong revenue figures, the company continues to navigate ongoing legal challenges regarding its intellectual property, particularly against Moderna and Pfizer/BioNTech.
Read more →ABUSArbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
Arbutus Biopharma has reacquired the rights to imdusiran from Qilu Pharmaceutical, concluding their strategic partnership. The company is focusing on advancing its pipeline efficiently, with imdusiran having shown promising results in achieving functional cures in patients. Additionally, Arbutus has established a new Scientific Advisory Board to guide its chronic hepatitis B virus treatment strategies.
Read more →ABUSArbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
Arbutus Biopharma Corporation reported its first quarter 2025 financial results, highlighting the success of their imdusiran therapy, which has functionally cured eight patients with chronic hepatitis B. Their oral PD-L1 inhibitor, AB-101, has demonstrated a strong safety profile and high receptor occupancy in early trials. The company also introduced Andrew J. Sung as General Counsel, enhancing their legal expertise. With a solid financial base of $113 million, Arbutus continues to focus on its clinical development efforts.
Read more →ABUSArbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025
Arbutus Biopharma presented promising clinical trial data for its HBV treatments, imdusiran and AB-101, at the EASL Congress 2025. Imdusiran achieved functional cure rates in chronic hepatitis B patients when combined with VTP-300 and low-dose nivolumab. AB-101 was shown to be safe and well-tolerated in a Phase 1a/1b trial, indicating high receptor occupancy without liver dysfunction.
Read more →About Arbutus Biopharma Corporation
Headquarters701 VETERANS CIRCLE, WARMINSTER, PA, 18974
Founded2005
BIOPHARMAWATCH ELITE PLUS
Trade the next ABUS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime